DrugPatentWatch Database Preview

Suvorexant - Generic Drug Details

  Purchase this report

or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for suvorexant and what is the scope of suvorexant patent protection?

Suvorexant is the generic ingredient in one branded drug marketed by Merck Sharp Dohme and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Suvorexant has fifty-four patent family members in thirty-five countries.

One supplier is listed for this compound.

Summary for suvorexant

International Patents:	54
US Patents:	1
Tradenames:	1
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	48
Clinical Trials:	22
Patent Applications:	49
DailyMed Link:	suvorexant at DailyMed

Pharmacology for suvorexant

Drug Class	Orexin Receptor Antagonist
Mechanism of Action	Orexin Receptor Antagonists P-Glycoprotein Inhibitors Cytochrome P450 3A Inhibitors

Synonyms for suvorexant

((7R)-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone

(R)-(4-(5-chlorobenzo[d]oxazol-2-yl)-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2H-1,2,3-triazol

(R)-(4-(5-Chlorobenzo[d]oxazol-2-yl)-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone

[(7R)-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone

081L192FO9

1030377-33-3

2737AH

5-Chloro-2-[(5R)-5-methyl-4-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-1,4-diazepan-1-yl]-1,3-benzoxazole

5-Chloro-2-[(5R)-5-methyl-4-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-1,4-diazepan-1-yl]-1,3-benzoxazole MK 4305

AB0072958

ACN-029994

AJ-110996

AK110529

AKOS022185167

BC600366

BCP0726000197

BDBM50318701

BELSOMRA

Belsomra (TN)

C23H23ClN6O2

CAS:1030377-33-3;MK-4305

CHEBI:82698

CHEMBL1083659

CS-0614

D00OVU

D10082

DB09034

DORA-analogue

DTXSID90145616

EX-A211

FT-0697203

GTPL2890

HE106661

HY-10807

J-690010

JYTNQNCOQXFQPK-MRXNPFEDSA-N

KB-78902

KS-0000062S

Methanone, ((7R)-4-(5-chloro-2-benzoxazolyl)hexahydro-7-methyl-1H-1,4-diazepin-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)-

Methanone, [(7R)-4-(5-chloro-2-benzoxazolyl)hexahydro-7-Methyl-1H-1,4-diazepin-1-yl][5-Methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]-

MFCD22377755

MK 4305

MK-4305

MK4305

MolPort-023-219-189

QCR-177

SC-94530

SCHEMBL1586289

ST2401560

SUV

Suvorexant (JAN/USAN)

Suvorexant (MK-4305)

Suvorexant [USAN:INN]

Suvorexant; MK 4305

Suvorexant(MK-4305)

UNII-081L192FO9

W-5905

ZINC49036447

US Patents and Regulatory Information for suvorexant

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569-004	Aug 13, 2014		RX	Yes	Yes			Y	Y
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569-003	Aug 13, 2014		RX	Yes	No
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569-002	Aug 13, 2014		RX	Yes	No
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569-001	Aug 13, 2014		RX	Yes	No

  Purchase this report

or, see our see our flat-rate plans

  Purchase this report

or, see our see our flat-rate plans

International Patents for suvorexant

Country	Document Number	Estimated Expiration
Brazil	PI0719361
Japan	4675427
New Zealand	577334
Japan	5767803